- Home
- LPTX vs CHRS Comparison
LPTX vs CHRS Comparison
Compare LPTX & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- CHRS
- Stock Information
- Founded
- LPTX 2011
- CHRS 2010
- Country
- LPTX United States
- CHRS United States
- Employees
- LPTX N/A
- CHRS 235
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LPTX Health Care
- CHRS Health Care
- Exchange
- LPTX Nasdaq
- CHRS Nasdaq
- Market Cap
- LPTX 119.6M
- CHRS 112.5M
- IPO Year
- LPTX N/A
- CHRS 2014
- Fundamental
- Price
- LPTX $0.36
- CHRS $0.99
- Analyst Decision
- LPTX Buy
- CHRS Strong Buy
- Analyst Count
- LPTX 2
- CHRS 4
- Target Price
- LPTX $8.00
- CHRS $5.26
- AVG Volume (30 Days)
- LPTX 381.5K
- CHRS 1.7M
- Earning Date
- LPTX 05-20-2025
- CHRS 05-12-2025
- Dividend Yield
- LPTX N/A
- CHRS N/A
- EPS Growth
- LPTX N/A
- CHRS N/A
- EPS
- LPTX N/A
- CHRS 0.25
- Revenue
- LPTX N/A
- CHRS $266,959,999.00
- Revenue This Year
- LPTX N/A
- CHRS N/A
- Revenue Next Year
- LPTX N/A
- CHRS $9.02
- P/E Ratio
- LPTX N/A
- CHRS $3.99
- Revenue Growth
- LPTX N/A
- CHRS 3.78
- 52 Week Low
- LPTX $0.22
- CHRS $0.66
- 52 Week High
- LPTX $4.79
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- LPTX 45.04
- CHRS 50.28
- Support Level
- LPTX $0.32
- CHRS $0.92
- Resistance Level
- LPTX $0.38
- CHRS $1.12
- Average True Range (ATR)
- LPTX 0.03
- CHRS 0.08
- MACD
- LPTX 0.00
- CHRS -0.01
- Stochastic Oscillator
- LPTX 37.36
- CHRS 30.99
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.